New Psilocybin-Like Drugs for Brain Receptor Diseases

This patent describes new chemical compounds similar to psilocin, found in 'magic mushrooms,' designed to activate specific brain receptors for treating various diseases.

What it covers

This patent focuses on creating new chemical compounds, referred to as "psilocin compounds" or "analogs," that are chemically similar to psilocin. These compounds are designed to act as "serotonin 5-HT2 receptor agonists," meaning they activate specific serotonin receptors in the brain. The goal is to use these new compounds in "pharmaceutical compositions" to treat medical conditions associated with these 5-HT2 receptors. For example, a new psilocin analog could be formulated into a pill to treat a mental health condition like depression, aiming to provide therapeutic benefits by modulating brain activity through these specific receptors. Due to the lack of available claims text, specific claim elements cannot be referenced.

What it doesn't cover

• —Does not cover natural psilocybin or psilocin compounds, only their specific synthetic 'analogs' or derivatives.
• —Does not cover compounds that do not primarily function as 'serotonin 5-HT2 receptor agonists'.
• —Does not cover non-chemical or non-pharmaceutical treatments for diseases associated with 5-HT2 receptors.
• —Does not cover methods of use that are not for the treatment of diseases.

The clever bit

The novelty lies in synthesizing new chemical structures, or 'analogs,' of psilocin. These analogs are engineered to interact with the brain's serotonin 5-HT2 receptors in specific ways, potentially offering advantages like improved stability, controlled duration of action, or reduced unwanted side effects compared to the natural compound.

Why it matters

Psilocybin and related compounds are being extensively researched for their potential to treat serious mental health conditions like depression, anxiety, and PTSD. This patent contributes to the development of novel drug candidates that could offer improved therapeutic profiles, such as better safety, efficacy, or duration of action, compared to naturally occurring psychedelics. It aims to expand the toolkit for addressing significant unmet medical needs in psychiatry and neurology.

Real-world examples

• 1.Novel psychedelic-assisted therapies for major depressive disorder
• 2.Drug candidates for generalized anxiety disorder
• 3.Pharmaceutical formulations for post-traumatic stress disorder (PTSD) treatment
• 4.Compounds for cluster headache treatment